Prehn R T
Department of Pathology, School of Medicine, University of Washington, Seattle 98195.
Cancer Res. 1993 Jul 15;53(14):3266-9.
A second tumor inoculum is often inhibited in its growth by the presence in the recipient animal of an earlier implanted, growing tumor. The tumor resulting from the first inoculum may, paradoxically, continue to grow despite the simultaneous inhibition of the growth of the second inoculum, a phenomenon usually called "concomitant immunity." Evidence now suggests that the phenomenon can be observed in the absence of any recognizable type of immune reaction and might often be named more appropriately "concomitant tumor resistance." Consideration of a variety of probably related observations suggests that concomitant tumor resistance can best be explained by the competitive interaction of two opposing influences: a local diffusible, tumor-facilitating environment, produced by both tumor and normal tissues, that is counteracted by circulating inhibitors that are also produced by both tumor and by normal tissues. In an implanted small tumor, because of geometric considerations and diffusion, the action of the local facilitating environment is weak; in a larger tumor the local facilitating environment has a relatively greater influence and thus the larger tumor can continue to grow despite levels of circulating tumor inhibitors capable of inhibiting the smaller growth.
在受体动物中,先前植入并正在生长的肿瘤的存在常常会抑制第二次接种肿瘤的生长。矛盾的是,尽管第二次接种肿瘤的生长同时受到抑制,但第一次接种产生的肿瘤可能会继续生长,这种现象通常称为“伴随免疫”。现在有证据表明,在没有任何可识别的免疫反应类型的情况下也能观察到这种现象,也许更恰当地将其命名为“伴随肿瘤抗性”。对各种可能相关的观察结果的思考表明,伴随肿瘤抗性最好用两种相反影响的竞争性相互作用来解释:肿瘤和正常组织都会产生局部可扩散的、促进肿瘤生长的环境,而肿瘤和正常组织也都会产生循环抑制剂来对抗这种环境。在植入的小肿瘤中,由于几何因素和扩散作用,局部促进环境的作用较弱;在较大的肿瘤中,局部促进环境具有相对更大的影响,因此尽管循环肿瘤抑制剂的水平能够抑制较小肿瘤的生长,但较大的肿瘤仍能继续生长。